Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2000

01-12-2000 | Paper Report

TNF-a suppresses CTGF expression

Author: John Campbell

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Excerpt

Collagen deposition is an essential part of normal tissue development and wound healing; however, excessive accumulation of collagen is central to fibrotic disorders such as scleroderma. The pleiotropic cytokine TGF? is an essential cytokine in normal tissue development, necessary for fibroblast proliferation and induction of collagen deposition. Transiently elevated TGF? levels induce collagen deposition in normal wound healing, but TGF? continues to be expressed during uncontrolled fibrotic events. TGF? is essential for induction of CTGF production by fibroblasts, resulting in collagen deposition. CTGF is overexpressed in fibrotic disorders; therefore, understanding the factors that mediate its action may be important in understanding them. This paper investigated the ability of TNF-a to suppress TGF?-induced CTGF production in normal fibroblasts. TGF? induction and TNF-a suppression of CTGF expression by normal fibroblasts was found to act through the same promoter in the CTGF gene. In scleroderma patients CTGF was constitutively produced, was enhanced by TGF? and could not be ablated with TNF-a. To examine the role of TNF-a in suppressing TGF?-induced CTGF in fibroblasts. …
Literature
1.
go back to reference Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A: Tumour necrosis factor-a suppresses the induction of connective tissue growth factor beta in normal and scleroderma fibroblasts. J Biol Chem. 2000, 275: 15220-15225.PubMedCrossRef Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A: Tumour necrosis factor-a suppresses the induction of connective tissue growth factor beta in normal and scleroderma fibroblasts. J Biol Chem. 2000, 275: 15220-15225.PubMedCrossRef
Metadata
Title
TNF-a suppresses CTGF expression
Author
John Campbell
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-2000-66820

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine